Welcome to our dedicated page for JUPITER NEUROSCIENCES SEC filings (Ticker: JUNS), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Jupiter Neurosciences, Inc. filings document a clinical-stage pharmaceutical issuer with common stock listed on the Nasdaq Capital Market and a business built around the JOTROL™ resveratrol platform and Nugevia™ products. Material-event reports cover standby equity purchase and registration-rights agreements, convertible promissory notes, amendments to installment provisions, and Nasdaq continued-listing notices.
Proxy materials disclose annual meeting matters, board governance and stockholder voting procedures. Rule 12b-25 notices document delayed periodic reports for annual and quarterly filings, while capital-structure disclosures address common stock, potential share issuances and related financing limitations.
JUPITER NEUROSCIENCES, INC. Chief Administrative Officer Alexander Gustaf Erik Rosen exercised equity awards into common stock. On 2 June 2025, he converted 96,608 Restricted Stock Awards and 164,554 Restricted Stock Units, each on a one-for-one basis into common shares at a $0.0000 exercise price, following the expiration of the IPO lock-up period.
Jupiter Neurosciences, Inc. director and Chief Scientific Officer Hayward Marshall A. reported multiple equity award exercises that increased his direct common stock holdings. On June 2, 2025 he exercised restricted stock awards and restricted stock units for a combined 789,195 shares of common stock. On March 2, 2026 he exercised a stock option for 225,000 shares of common stock at a conversion price of $0.01 per share, ahead of the option’s March 15, 2026 expiration. In total, the transactions reflect exercises of 1,014,195 shares from derivative awards into common stock, resulting in 2,995,077 common shares held directly after the most recent transaction. Footnotes state that the derivative securities convert into common stock on a one-for-one basis and that certain awards vested upon expiration of the IPO lock-up period or under the company’s 2016 Equity Incentive Plan.
Jupiter Neurosciences, Inc. director Nicholas H. Hemmerly exercised restricted stock units into common stock. On June 2, 2025, 95,550 restricted stock units converted on a one-for-one basis into 95,550 shares of common stock, vesting upon expiration of the lock-up period for the company’s initial public offering. Following the transaction, Hemmerly holds 95,550 common shares directly, and the reported restricted stock unit position is reduced to zero. The event reflects equity compensation vesting rather than an open-market purchase or sale.
JUPITER NEUROSCIENCES, INC. director Holger Weis exercised 85,800 Restricted Stock Units that converted into an equal number of common shares on June 2, 2025. The RSUs vested upon expiration of the lock-up period for the company’s initial public offering. Following the transaction, Weis holds 96,581 common shares directly.
JUPITER NEUROSCIENCES, INC. director Tomas Jan Philipson received a grant of stock options as board compensation. He was awarded 536,428 stock options, each for one share of common stock at an exercise price of $0.21 per share. Of this grant, 90,000 options relate to his appointment to the Board of Directors, and 446,428 options were granted instead of cash for his annual board retainer and committee fees. The options vest in 12 equal quarterly installments beginning on September 2, 2026, as long as he continues to serve as a director through each vesting date, and are scheduled to expire on June 29, 2036.
JUPITER NEUROSCIENCES, INC. director Tomas Jan Philipson filed an initial Form 3 reporting his status as a director and not a ten percent owner. The filing shows no insider transactions, exercises, gifts, or tax withholdings and provides no derivative holdings information at this time.
Jupiter Neurosciences, Inc. filed a prospectus supplement dated June 30, 2026 that incorporates a Form 8-K reporting the appointment of Tomas J. Philipson, Ph.D. to the Board effective June 26, 2026.
The Board named Dr. Philipson to the Audit and Compensation Committees. In lieu of cash, Dr. Philipson will receive a sign-on option for 90,000 shares and an option in lieu of annual cash retainer for 446,428 shares, each vesting quarterly over 36 months with a Grant Date of June 29, 2026. Shares trade on Nasdaq under JUNS; closing price was $0.21 on June 29, 2026.
Jupiter Neurosciences appointed Tomas J. Philipson, Ph.D., a 64-year-old health care economist with extensive academic, government, and industry experience, to its Board of Directors effective June 26, 2026. He will serve until the next annual stockholder meeting, unless he departs earlier.
He was also appointed to the Board’s Audit Committee and Compensation Committee. In lieu of standard cash fees for non-employee directors, he will receive stock options, aligning his compensation with the company’s long-term performance.
Jupiter Neurosciences, Inc. is registering 16,000,000 shares of common stock for resale by YA II PN, LTD (Yorkville) under a Standby Equity Purchase Agreement (SEPA). These “Advance Shares” may be issued at Jupiter’s discretion through one or more Advances.
The SEPA provides up to $20.0 million in potential equity financing, of which $2.8 million has already been raised through earlier sales and related convertible notes. As of June 17, 2026, Jupiter had 48,224,110 shares outstanding; if all 16,000,000 registered shares were issued, they would represent about 24.9% of total shares and 31.6% of non‑affiliate shares, meaning meaningful potential dilution to existing holders.
Jupiter is a clinical-stage pharmaceutical company developing JOTROL™, an enhanced resveratrol formulation targeting central nervous system disorders including Parkinson’s disease, and commercializing its Nugevia™ longevity and wellness supplement line. The company expects SEPA proceeds to primarily support a Phase 2 Parkinson’s trial, expand direct‑to‑consumer Nugevia marketing, and fund general corporate purposes.